---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-283537"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:48:22.888133+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q3 commercial rev $9.0M, up 30%; raises FY guidance; pivotal trial endpoints met

## Summary
- Commercial revenue (ex-BARDA) $9.0M, +30% YoY; total revenue $9.1M.
- Net loss $5.6M ($0.22/sh); cash $88.2M, no debt.
- Soft-tissue repair trial met co-primary endpoints; vitiligo trial achieved super-superiority.
- FY 2022 commercial revenue guidance raised to $33-34M from $30M.
- Japan MHLW grants RECELL approval; partner COSMOTEC launching in Q4 2022.

## SEC filing metadata
- accession: 0001193125-22-283537
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/0001193125-22-283537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/d384818d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-283537
- JSON: https://secwatch.observer/filing/0001193125-22-283537.json
- Plain text: https://secwatch.observer/filing/0001193125-22-283537.txt

## Key facts
- Earnings Releases
  AVITA Medical, Inc. reported full year 2022 results: revenue $33.0-34.0 million. Guidance raised.
  - Period: full year 2022
  - Revenue: $33.0-34.0 million
  - Guidance: raised
  - Result: guidance update
  source text: full year 2022 commercial revenue (excluding BARDA revenues) is expected to be $33.0-34.0 million, an increase from our prior guidance of $30 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/0001193125-22-283537-index.htm
- Earnings Releases
  AVITA Medical, Inc. reported third quarter ended September 30, 2022 results: revenue $9.0 million, net income $5.6 million, EPS $0.22 per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $9.0 million
  - Net income: $5.6 million
  - EPS: $0.22 per share
  - Result: reported results
  source text: Reported commercial revenue, which excludes BARDA revenue, of $9.0 million, a 30% increase compared to $6.9 million in the corresponding period in the prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/0001193125-22-283537-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.